Bayer's Nexavar reaches under 1% of Indian patients, claims Natco in compulsory licensing case
This article was originally published in Scrip
Executive Summary
Bayer's anticancer Nexavar (sorafenib tosylate) reaches less than 1% of the100,000 patients who need them in India, according to Natco Pharma, which has filed a request for a compulsory licence for the product, citing limited availability as one of the grounds.